Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
Top Cited Papers
- 20 January 2006
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 5 (2) , 160-170
- https://doi.org/10.1038/nrd1958
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.Keywords
This publication has 89 references indexed in Scilit:
- Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosisThe Journal of cell biology, 2005
- Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegenerationFEBS Letters, 2004
- Turning down, but not offNature, 2004
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantineCell Death & Differentiation, 2003
- Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular DementiaStroke, 2002
- Saving the Nerve from Glaucoma: Memantine to CaspacesSeminars in Ophthalmology, 1999
- Transcriptional or translational inhibition blocks low dose NMDA-mediated cell deathNeuroReport, 1995
- Delayed administration of memantine prevents N‐methyl‐D‐aspartate receptor‐mediated neurotoxicityAnnals of Neurology, 1993
- Evidence that the Loss of the Voltage‐Dependent Mg2+ Block at the N‐Methyl‐D‐Aspartate Receptor Underlies Receptor Activation During Inhibition of Neuronal MetabolismJournal of Neurochemistry, 1992